Actinogen Medical Ltd. has announced the enrollment of the 100th participant in its XanaMIA phase 2b/3 trial of Xanamem® for Alzheimer's disease. The company plans an interim analysis in January 2026, with final trial results expected in late 2026. An independent Data Monitoring Committee will review patient data during the interim analysis to ensure the trial's safety and efficacy. Additionally, Actinogen is preparing for a Type C meeting with the FDA in the second half of 2025 to discuss regulatory approval pathways for Xanamem, including potential expedited pathways if the trial demonstrates strong efficacy and safety. The full enrollment target is set at 220 participants to robustly demonstrate the safety and efficacy of the oral Xanamem 10mg daily dosage. Results from the trial have not yet been presented and are anticipated in the future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。